Quick Answer
Sarepta Therapeutics, Inc. reported Operating Income Loss of -$699.78 million for the year ending 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -420.9% in Operating Income Loss from 2024 to 2025.
- This data is from Sarepta Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), Sarepta Therapeutics, Inc.'s Operating Income Loss has declined by 4,412.7%.
- Historical annual values: Fiscal year 2025: -$699.78 million | Fiscal year 2024: $218.08 million | Fiscal year 2023: -$267.82 million | Fiscal year 2022: -$536.20 million | Fiscal year 2021: -$459.71 million | Fiscal year 2020: -$564.16 million | Fiscal year 2019: -$705.56 million | Fiscal year 2018: -$343.63 million | Fiscal year 2017: -$171.64 million | Fiscal year 2016: -$266.73 million | Fiscal year 2015: -$220.18 million | Fiscal year 2014: -$133.79 million | Fiscal year 2013: -$90.28 million | Fiscal year 2012: -$29.70 million | Fiscal year 2011: -$35.93 million | Fiscal year 2010: -$20.93 million | Fiscal year 2009: -$15.51 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: